Short answer
10x Genomics, Inc. (TXG) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for the quarter ended June 30, 2026.
10x Genomics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for the quarter ended June 30, 2026
- Full revenue, earnings, guidance and operating details in Exhibit 99.1, the accompanying earnings release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $151.0M, down from $172.9M, but underlying revenue excluding settlements grew 3% year over year
- Consumables revenue $130.8M, up from $122.2M, offset by instrument revenue falling to $7.7M from $14.5M
- Gross margin 74%, up from 72%, helped by lower manufacturing costs and $2.6M in tariff refunds
- Net loss $17.9M, or $0.14 per share, versus net income $34.5M, or $0.28, due largely to smaller settlement gains
- Full-year revenue guidance raised to $610M-$630M, signaling improved confidence despite continued operating losses and $552.0M liquidity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other 10x Genomics, Inc. 8-K filings
Get the next TXG 8-K as it lands
Follow TXG for push alerts, or ask the research agent what this filing means.